6 completed. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 2 | Completed 2 |
Follow Porphyria, Acute Intermittent: new trials by email Literature Review of Porphyria, Acute Intermittent trials Research Report on Porphyria, Acute Intermittent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP) Givosiran, 5-probe cocktail - Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP) | Phase 1 | Completed | Alnylam Pharmaceuticals | 10 | 2018-04-26 | 2019-03-12 |
| Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride Chlorpromazine Hydrochloride - Anti-Psychotic, Management of Manifestations of Psychotic Disorders | Phase 1 | Completed | Cycle Pharmaceuticals Ltd. | 20 | 2016-11-01 | 2017-11-14 |
| A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) Givosiran - Acute Intermittent Porphyria | Phase 1 / Phase 2 | Completed | Alnylam Pharmaceuticals | 16 | 2016-10-01 | 2024-03-12 |
| A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl) - Acute Intermittent Porphyria | Phase 1 | Completed | Alnylam Pharmaceuticals | 40 | 2015-05-06 | 2018-06-14 |
| Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria rAAV2/5-PBGD vector dosage 1, rAAV2/5-PBGD vector dosage 2, rAAV2/5-PBGD vector dosage 3 - Acute Intermittent Porphyria | Phase 1 | Completed | Digna Biotech S.L. | 8 | 2012-11-01 | 2014-12-18 |
| Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria heme arginate, tin mesoporphyrin - Porphyria | Phase 1 / Phase 2 | Completed | National Center for Research Resources (NCRR) | 59 | 1993-07-01 | 2005-06-24 |
Porphyrias (5) · Coproporphyria, Hereditary (1) · Metabolism, Inborn Errors (1) · Rare Diseases (1) · Vomiting (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Digestive System Diseases (6) · Genetic Diseases, Inborn (6) · Liver Diseases (6) · Metabolic Diseases (6) · Nutritional and Metabolic Diseases (6) · Porphyrias, Hepatic (6) · Skin Diseases (6) · Skin Diseases, Genetic (6) · Skin and Connective Tissue Diseases (6) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Pathologic Processes (1) · Porphyrias (1) · Signs and Symptoms (1)
givosiran (3) · Chlorpromazine (1) · Tablets (1) · heme arginate (1) · tin mesoporphyrin (1)
Alnylam Pharmaceuticals (3) · Cycle Pharmaceuticals Ltd. (1) · Digna Biotech S.L. (1) · National Center for Research Resources (NCRR) (1)
Sweden (3) · United Kingdom (2) · United States (2) · South Africa (1) · Spain (1)
Amy Simon, MD (1) · Dr. Yolandi Swart, FCPHM(SA) (1) · Jesus Prieto, MD (1) · Juan Ruiz, MD (1) · Karl Elmo Anderson (1) · Nader Najafian, MD (1) · Rafael Enriquez de Salamanca, MD (1)
PMID 39363243, PMID 27212246, PMID 30726693
2016 (1)